U.S. Markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
112.92-0.92 (-0.81%)
At close: 4:00PM EDT

112.91 -0.01 (-0.01%)
After hours: 7:57PM EDT

People also watch
BMRNSGENACORACADALXN
Full screen
Previous Close113.84
Open112.92
Bid112.10 x 300
Ask113.00 x 200
Day's Range108.12 - 117.44
52 Week Range31.38 - 117.44
Volume4,537,182
Avg. Volume1,159,389
Market Cap10.36B
Beta3.21
PE Ratio (TTM)-22.04
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance
    Investor's Business Daily7 hours ago

    Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance

    Alnylam could enter a new chapter in 2018 as it transitions into a commercial-stage company, an analyst said Thursday.

  • Barrons.com7 hours ago

    Alnylam Pharmaceuticals: Bet or Fold?

    When a small drug company’s surges almost 52% in a single day after releasing impressive clinical trial results for a potentially revolutionary class of drugs, should investors cash in or go all in? In the case of Alnylam Pharmaceuticals (ALNY), the answer depends on which sell-side analyst happens to be speaking. Instinet’s Christopher Marai advises investors to “sell on the data.” The strong late-stage study results released yesterday for the company’s Patisiran therapy, a RNAi therapeutic, are already baked into the stock price, which sat almost unchanged today at $113.52 a share.

  • Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up
    Zacks12 hours ago

    Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up

    Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.